Marketed in 33 countries across Europe, the Americas, Asia, and North Africa, Zestril is a globally distributed brand of lisinopril, classified within the group of agents acting on the renin-angiotensin system. For an international reader, that wide footprint matters: Zestril is one of the brands most likely to be recognised at a pharmacy counter abroad, even if the local equivalent ends up being a generic version of the same molecule.
Lisinopril is prescribed in the management of hypertension, heart failure, and the cardiovascular care of patients after a heart attack, as well as in the protection of kidney function in diabetes-related nephropathy. The structured indication block further down this page lists each registered use as recognised by the regulators in the markets where Zestril is sold, and reflects the medication's combined antihypertensive, vasodilator, cardioprotective, and nephroprotective profile.
Travellers and expatriates frequently encounter lisinopril abroad — sometimes labelled as Zestril, sometimes under another brand name, and very often as a generic. Markets where the brand is registered include Japan, Brazil, France, Canada, and Indonesia, but packaging, naming conventions, and prescription pathways vary considerably from one country to another. A pharmacist in the destination country can usually confirm whether a locally available lisinopril product corresponds to what the patient was previously taking.
Other medications acting on the renin-angiotensin system are also distributed widely under different molecules and brand names, and they are not freely interchangeable. Anyone taking Zestril regularly, considering it, or trying to identify a local equivalent should treat any change as a clinical decision and discuss it with a healthcare provider familiar with their full medical history.
Shelf life
4 years.
Incompatibilities
Not applicable.
List of excipients
Mannitol
Calcium Hydrogen Phosphate dihydrate
Red Iron Oxide (E172)
Maize Starch
Pregelatinised Starch
Magnesium Stearate
Date of revision of the text
5th October 2017
Marketing authorisation holder
AstraZeneca UK Limited,
600 Capability Green,
Luton, LU1 3LU, UK.
Special precautions for storage
Do not store above 30°C
Nature and contents of container
5 mg Tablets:
Aluminium/PVC-PVDC or Aluminium/PVC foil blister packs of 14, 20, 28, 28x1, 30, 42, 50, 56, 60, 84, 98, 100, 400 and 500 tablets.
Aluminium/PVC-PVDC or Aluminium/PVC foil blister calendar packs of 14, 28, 42, 56, 84 and 98 tablets.
HDPE bottle packs of 20, 30, 50, 100 and 400 tablets.
10 mg Tablets:
Aluminium/PVC-PVDC or Aluminium/PVC foil blister packs of 14, 20, 28, 30, 50, 56, 84, 98, 100 and 400 tablets.
Aluminium/PVC-PVDC or Aluminium/PVC foil blister calendar packs of 14, 28, 56, 84 and 98 tablets.
HDPE bottle packs of 20, 30, 50, 100 and 400 tablets.
20 mg Tablets:
Aluminium/PVC-PVDC or Aluminium/PVC foil blister packs of 14, 20, 28, 30, 42, 50, 56, 56x1, 60, 84, 98, 100, 400 and 500 tablets.
Aluminium/PVC-PVDC or Aluminium/PVC foil blister calendar packs of 14, 28, 42, 56, 84 and 98 tablets.
HDPE bottle packs of 20, 30, 50, 100 and 400 tablets.
Not all pack sizes may be marketed.
Marketing authorisation number(s)
| 5 mg:
| PL 17901/0061
|
| 10 mg:
| PL 17901/0062
|
| 20 mg:
| PL 17901/0063
|
Special precautions for disposal and other handling
No special requirements.
Date of first authorisation/renewal of the authorisation
Date of first authorisation: 8 June 2000
Date of first renewal: 1 August 2010
